InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,447.87
(
-0.31%
)
US TECH 100
19,037.60
(
0.42%
)
Dow Jones
39,411.21
(
0.67%
)
Brent Oil
84.85
(
-0.49%
)
Bitcoin
61,502.41
(
2.07%
)
Post# of 376163
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Manti

Send PM Follow Ignore
Followers 256
Posts 17561
Boards Moderated 1
Alias Born 07/10/2003

Manti

Re: None

Thursday, 03/27/2014 3:20:32 PM

Thursday, March 27, 2014 3:20:32 PM

Post# of 376163
Gapper IDRA. Selling waaaay over done, and Piper Jaffray reiterates overweight with 7 price target.

March 27, 2014
12:46 EDT IDRA Idera Pharmaceuticals weakness seems overdone, says Piper Jaffray
After Idera's stock tumbled 45%, Piper Jaffray thinks the company's Phase II IMO-8400 psoriasis data, due next week, will show on-target efficacy and show the drug is safe. The firm reiterates a $7 price target and Overweight rating on the shares


Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up